Epidemiology of ANCA vasculitis in Northern Spain.

ANCA antineutrophil cytoplasmic antibody-associated vasculitis epidemiology granulomatosis with polyangiitis incidence microscopic polyangiitis prevalence

Journal

Rheumatology (Oxford, England)
ISSN: 1462-0332
Titre abrégé: Rheumatology (Oxford)
Pays: England
ID NLM: 100883501

Informations de publication

Date de publication:
06 Aug 2024
Historique:
received: 07 06 2024
revised: 22 07 2024
accepted: 24 07 2024
medline: 7 8 2024
pubmed: 7 8 2024
entrez: 6 8 2024
Statut: aheadofprint

Résumé

The incidence of anti-neutrophil cytoplasmic antibodies (ANCA) associated vasculitis (AAV) shows disparate results due to variable classification criteria and heterogeneous-population series. We aimed to estimate the incidence of AAV in a well-defined population with standardized classification criteria. Population-based study of AAV patients diagnosed from January 2000 to December 2023 in Cantabria, Northern Spain. Patients were classified according to ACR/EULAR 2022 into granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), or unclassified vasculitis if the criteria were not met. Eosinophilic granulomatosis with polyangiitis (EGPA) patients were not included. The annual incidence rates were estimated by cases over 1,000 000 (106) (95% CI) including overall AVV, type of AAV, sex, and year of diagnosis. A literature review was also performed. We included 152 (80/72 men; mean age; 70.6 ± 13.18 years) patients. They were classified as MPA (67; 44%), GPA (64; 42.2%), and unclassified vasculitis (21; 13.8%). Annual incidence was 13.4 (10-16.8)/106 [male 14.5 (10.5-18.5); female 12.1 (8.7-15.6)]. The Annual incidence of MPA was 5.9 (4-7.8)/106 and GPA 5.6 (3.9-7.3)/106. The mean Annual incidence increased from 6.1 (4.5-7.7)/106-16.5 (5.6-27.4)/106 in the last three years, particularly, in GPA from 2.3 (0.3-4.9)/106-8.2 (2-14.5)/106. The prevalence of AAV was 184.7 (181-188)/106. During a 20-year period we found that the incidence of AAV (GPA and MPA) in Northern Spain is higher than Southern Spain, but lower than Northern European countries. An increase in the incidence was observed in the last years.

Identifiants

pubmed: 39107884
pii: 7728461
doi: 10.1093/rheumatology/keae413
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© The Author(s) 2024. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Auteurs

Fabricio Benavides-Villanueva (F)

Rheumatology, Spain Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain.

Alba Herrero-Morant (A)

Rheumatology, Spain Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain.

Diana Prieto-Peña (D)

Rheumatology, Spain Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain.

Salma Al Fazazi (SA)

Former fellow, actual position, Rheumatology, Malaga University Hospital.

Vanesa Calvo-Río (V)

Rheumatology, Spain Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain.

Mónica Renuncio-García (M)

Immunology, Spain Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain.

Adrián Martín-Gutierrez (A)

Rheumatology, Spain Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain.

María Del Amparo Sánchez-Lopez (M)

Dermatology, Spain Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain.

Claudia Poo-Fernandez (C)

Pneumology, Santander, Spain Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain.

Clara Escagedo-Cagigas (C)

Nephrology, Spain Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain.

María Rodríguez-Vidriales (M)

Dermatology, Spain Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain.

Ricardo Blanco (R)

Rheumatology, Spain Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain.

Classifications MeSH